The BCR-ABL RT-PCR (Qualitative) Test in Pune detects the BCR-ABL gene mutation linked to chronic myeloid leukemia, providing essential insights for diagnosis and treatment planning.
BCR-ABL RT-PCR (Qualitative) is a critical diagnostic test used to detect the presence of the BCR-ABL fusion gene, which is associated with chronic myeloid leukemia (CML) and some types of acute lymphoblastic leukemia (ALL). This test employs the reverse transcription polymerase chain reaction (RT-PCR) technique, allowing for the sensitive and specific identification of the BCR-ABL transcript in blood or bone marrow samples.
The BCR-ABL RT-PCR test is designed to identify the BCR-ABL gene rearrangement that occurs when the BCR gene on chromosome 22 fuses with the ABL gene on chromosome 9. This fusion results in the production of a tyrosine kinase that drives uncontrolled cell proliferation, leading to leukemia. The qualitative aspect of the test determines whether the fusion gene is present, which is crucial for the diagnosis and monitoring of leukemia.
The BCR-ABL RT-PCR (Qualitative) test is vital for diagnosing CML and determining the most appropriate treatment options. Early detection of the BCR-ABL gene can help in:
Confirming Diagnosis: Establishing a definitive diagnosis of CML or ALL based on the presence of the fusion gene.
Monitoring Treatment Response: Tracking the effectiveness of targeted therapies, such as tyrosine kinase inhibitors, and assessing disease progression or relapse.
Prognosis Evaluation: Providing insights into the likely course of the disease based on genetic markers.
Patients Diagnosed with CML or ALL: Individuals suspected of having chronic myeloid leukemia or acute lymphoblastic leukemia based on clinical symptoms and blood tests should undergo this test.
Patients Monitoring Response to Therapy: Those already diagnosed with CML and undergoing treatment can benefit from this test to evaluate their response to therapy.
Individuals with a Family History of Leukemia: Patients with a significant family history of hematological malignancies may consider this test for early detection.
At Diagnopein in Pune, we offer the BCR-ABL RT-PCR (Qualitative) test with a commitment to excellence in patient care. Our laboratory utilizes advanced technology and state-of-the-art equipment to ensure accurate and reliable results. With a focus on cleanliness and hygiene, we maintain a safe testing environment for our patients. Additionally, we provide affordable pricing without compromising quality, supported by our team of experienced professionals who are dedicated to your health.
The test involves drawing a blood sample or obtaining a bone marrow aspirate, which is then analyzed in the laboratory using RT-PCR technology to detect the BCR-ABL fusion gene.
A positive result indicates the presence of the BCR-ABL fusion gene, confirming a diagnosis of chronic myeloid leukemia or acute lymphoblastic leukemia.
The test involves a standard blood draw or bone marrow aspiration, which may cause minor discomfort but is generally quick and well-tolerated.
Results are typically available within a few days, depending on laboratory processing times and demand.
